Collaborations with partners like BioNTech, Regeneron and WuXi Biologics further underscore the platform’s capabilities and its potential to revolutionize cancer treatment. This press release contains ...

Collaboration will Leverage Solidion's Patent Portfolio and Drive U.S. Manufacturing DALLAS, Nov. 11, 2024 /PRNewswire/ -- Solidion Technology, Inc. (NASDAQ: STI), an advanced battery technology ...

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced the results of the November 2024 Index Review for the MSCI Equ ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...

Application error: a client-side exception has occurred (see the browser console for more information).

European markets are expected to start the week on a mostly positive note Monday, with all eyes on Tuesday's presidential ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...

Taiwan reports Chinese warplanes and warships around island China angered by $2 bln US arms package for Taiwan China views Taiwan as its own territory TAIPEI/BEIJING, Oct 27 (Reuters) - Taiwan's ...

KAOHSIUNG, TAIWAN – Contrary to what much of the world’s media has reported, China’s 13-hour simulated blockade of Taiwan that began on Monday, Oct. 14, using a record-breaking number of ...

Soldiers must "enhance their strategic deterrent and combat capability," Xi said. China, which claims Taiwan as part of its territory, has stepped up its shows of force around the self-ruled ...

Could SEAL Team 6 special operators help Taiwan fend off a Chinese invasion? That is what the elite special operations unit has been preparing for over a year, according to recent reporting from ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...